相关实验视频
Updated: Jun 26, 2025

08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.2K
与炎症酶相关的基因特征作为骨髓肉瘤的预后生物标志物
Nan Zhang1, Ying Han2,3, Hangkai Cao4
1Department of Medical Oncology, China Coast Guard Hospital of the People's Armed Police Force, Zhejiang, China.
Journal of cellular and molecular medicine
|May 14, 2024
概括
这项研究确定了骨髓瘤中炎症组基因特征,揭示了高FGFR3和RARB表达与生存率差相关. 新型生物标志物CD36和MYD88显示出对骨癌的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 骨髓瘤是一种常见于年轻人中的侵袭性骨癌.
- 它的转移潜力需要改进预后标志物和治疗点.
研究的目的:
- 为了研究在骨髓瘤中与炎症相关的基因特征的预后价值.
- 为了确定风险分层和潜在的治疗干预的新生物标志物.
主要方法:
- 基于基因表达的共识聚类来定义基于基因表达的患者子组.
- 免疫分析分析免疫细胞透.
- 机器学习算法 (StepCox,梯度提升) 用于预测模型开发.
- 在体外实验验证基因功能的验证.
主要成果:
- 确定了三个患者子组;一个与高FGFR3和RARB相关的生存率差.
- 开发了一个预后模型 (c指数为0.706),突出CD36和MYD88.8.
- 较高的炎症体风险得分与数据集中的生存率降低相关.
- 在体外研究证实CD36和MYD88促进骨髓瘤细胞的增殖和侵入.
结论:
- 炎症酶基因特征是骨髓瘤的关键预后指标.
- CD36和MYD88代表了有前途的生物标志物和治疗点.
- 这些发现支持个性化治疗策略,以改善骨髓瘤患者的治疗结果.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K

